GLP1s cut drinking for ~50% of prior drinkers.
Weight Watchers looks structurally pressured by GLP1-driven alcohol reduction, weakening its core relevance despite the behavioral program model.
GLP1s appear to reduce alcohol consumption after patients start the drug, with ~50% of prior drinkers cutting intake in the study. That directly attacks the behavioral niche Weight Watchers monetizes, making the booze-company and weight-loss ecosystem outlook feel less promising for WW.
"Big Alcohol’s Ozempic Problem"